Showing 3351-3360 of 4063 results for "".
- New Phase 3 Data Show Genentech’s Vabysmo Improved Vision and Reduced Retinal Fluid in People with RVOhttps://modernod.com/news/new-phase-3-data-show-genentechs-vabysmo-improved-vision-and-reduced-retinal-fluid-in-people-with-rvo/2481401/Genentech announced positive new data from two global phase 3 studies, BALATON and COMINO, evaluating Vabysmo (faricimab-svoa) in macular edema due to branch and central retinal vein occlusion (BRVO and CRVO) at 24 weeks. The studies showed that treatment with Vabysmo resulted in
- Radiance Therapeutics to Present at Glaucoma 360 New Horizons Forumhttps://modernod.com/news/radiance-therapeutics-to-present-at-glaucoma-360-new-horizons-forum/2481398/Radiance Therapeutics announced that Laurence Marsteller, MD, Chief Executive Officer, will present the company at the Glaucoma Research Foundation headline event, Glaucoma 360 New Horizons 2023, that will take place on February 3, 2023 in San Francisco. The Radiance Therapeut
- Viridian Appoints Scott Myers as President and Chief Executive Officerhttps://modernod.com/news/viridian-appoints-scott-myers-as-president-and-chief-executive-officer/2481388/Viridian Therapeutics has appointed Scott Myers as President and Chief Executive Officer, as well as a member of the Board of Directors, effective February 6, 2023. He succeeds Jonathan Violin, PhD, who has led Viridian since its inception in 2020. “Our progres
- Clearside Biomedical Announces Leadership Changeshttps://modernod.com/news/clearside-biomedical-announces-leadership-changes/2481386/Clearside Biomedical announced that its Chief Medical Officer and Chief Development Officer, Thomas A. Ciulla, MD, will transition to the role of Chief Medical Advisor-Retina for Clearside and step down from his full-time position, effective February 17, 2023. In his new advisory capacity, Dr. Ci
- CDC Provides Update on Pseudomonas Aeruginosa Associated with Artificial Tearshttps://modernod.com/news/cdc-provides-update-on-pseudomonas-aeruginosa-associated-with-artificial-tears/2481382/The Centers for Disease Control and Prevention (CDC) issued a Health Alert Network (HAN) Health Advisory in regards to infections of 55 people in 12 states related to the use of artificial tears. Patients with infections reported more than 10 different brands of artifici
- Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX in Wet AMDhttps://modernod.com/news/clearside-biomedical-announces-positive-6-month-results-from-oasis-extension-study-with-suprachoroidal-cls-ax-in-wet-amd/2481380/Clearside Biomedical announced positive results from the extension study of its OASIS phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) administered by suprachoroidal injection via Clearside’s SCS Microinjector in wet age-related macular degeneration (AMD) parti
- Roche Names Teresa Graham Head of its Pharma Businesshttps://modernod.com/news/roche-names-teresa-graham-head-of-its-pharma-business/2481379/Teresa Graham, former Genentech executive and current Head of Global Product Strategy for Roche Pharmaceuticals, has been appointed CEO of Roche Pharmaceuticals, based in Basel, Switzerland, effective March 2023. She will also become a member of the Corporate Executive Committee.</
- Harrow Announces Permanent, Product-Specific J-Code for Iheezo for Ocular Surface Anesthesiahttps://modernod.com/news/harrow-announces-permanent-product-specific-j-code-j2403-for-iheezo-for-ocular-surface-anesthesia/2481378/Harrow announced that the Centers for Medicare & Medicaid Services (CMS) has issued a permanent, product-specific J-code for Iheezo (chloroprocaine hydrochloride ophthalmic gel) 3% for ocular surface anesthesia. Under the Healthcare Common Procedure Coding System (HCPCS), the Iheezo J‑co
- CXL Ophthalmics Appoints Jonathan Talamo, MD, as Chair of the Boardhttps://modernod.com/news/cxl-ophthalmics-appoints-jonathan-talamo-md-as-chair-of-the-board/2481355/CXL Ophthalmics announced that Jonathan Talamo, MD, has been appointed as its new Chair of the Board of Directors. Dr. Talamo has served as a Board member for the company since 2020. CXLO is developing a minimally-invasive treatment for ectatic corneal disease. The company's Ep
- Staar Surgical Announces Partnership with Actress Peyton Listhttps://modernod.com/news/staar-surgical-announces-partnership-with-actress-peyton-list/2481344/Staar Surgical announced a partnership with actress and beauty entrepreneur, Peyton List, to promote the EVO Implantable Collamer Lenses (EVO), which recevied FDA approval in 2022 for the correction of myopia with or without astigmatism. In December 2022, Ms. Li